Navigation Links
Latest Salvo Fired in Frozen Yogurt Wars as Southern California's Fastest-Growing Franchise - Cefiore - Launches New Chocolate Flavor
Date:2/12/2008

yogurt flavors, including: Raspberry Pomegranate, Green Tea, Original and the newest flavors, Acai Berry and Chocolate. Each serving comes topped with fresh fruit. The company also offers fruit smoothies, flavored snow ice, waffles, and a wide selection of organic teas and coffee drinks. Please visit http://www.cefiore.com for more information.

Cefiore is a subsidiary of worldwide seafood and sushi buffet franchise, Todai. Todai SSB, Inc. develops, franchises, and licenses sushi and seafood buffet restaurants under the "Todai" name. The first Todai opened in Southern California in 1985. Please visit http://www.todai.com for more information


'/>"/>
SOURCE Cefiore
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cejka Search Experts Present Latest Developments in Physician Retention and CEO Leadership Skills
2. Teens, Young Adults Missing Out on Latest Cancer Advances
3. Latest Study Says Statins Dont Slow Alzheimers
4. Cancer study finds adolescents dont get same access to latest treatments as younger patients
5. Statement from AAJ President Kathleen Flynn Peterson on ATRAs Latest Attack on Civil Justice Attorneys
6. A Whole New Sandwich Debuts in the Freezer Aisle: LEAN POCKETS(R) Brand Introduces Latest Whole Grain Varieties
7. AST Emergence to Convergence Highlights the Latest High-Risk Organ Donor and Recipient Issues
8. Latest Edition of Ripon Forum Highlights Schwarzeneggers Leadership on Another Challenge Facing his State - Health Care
9. Cejka Search Experts Present Latest Developments in Physician and Healthcare Employment at Leading Industry Conferences
10. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
11. Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory 2Health News:Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory 3Health News:Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory 4Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 3Health News:Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals 2Health News:Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance 2Health News:Informed-Choice Reinforces Need to Test Supplements for Inadvertent Contamination After Recent NFL Players' Positive Tests 2Health News:Pharmasset to Webcast an Investor Event from the AASLD Meeting 2Health News:Pharmasset to Webcast an Investor Event from the AASLD Meeting 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2